John D. Trzupek
Worldwide Medicinal Chemistry, Pfizer Worldwide R&D, Cambridge, MA 02140, USA
John Trzupek has four years of experience as a medicinal chemist in the design and synthesis of drug-like molecules for inflammation and metabolic disorders at Pfizer R&D in Cambridge, MA. He obtained his BA with honors in chemistry at Northwestern University in 2001 before moving to The Scripps Research Institute, where as an NDSEG predoctoral fellow, he earned his Ph.D under the supervision of Professor Dale Boger in 2006. John then completed his postdoctoral research with Professsor Samuel Danishefsky at the Memorial Sloan–Kettering Cancer Center in NY in 2008, and he is currently pursuing an MBA from The University of Chicago Executive MBA program.
During his research career John has delivered four invited lectures and is also an author on fourteen research papers and patents. In 2011 he was the recipient of the Pfizer BioTherapeutics Chemistry Design of the Year Award. Today, John is a member of the BioTherapeutics External Chemistry Innovation group at Pfizer working with the Structural Genomics Consortium on epigenetic targets.
Chemical Probes for Epigenetics
Research into epigenetics has great promise to enable future drug discovery in many therapeutic areas. This presentation will highlight the discovery of novel chemical probes for epigenetic proteins discovered in collaboration with the Structural Genomics Consortium that may have an important role in disease.